Biogen Inc. (BIIB)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Biogen Inc. currently loses $1.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 5
in 78 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Biogen beat expectations on both the top and bottom line in the third fiscal quarter of 2026, based on preliminary results reported October 28, 2026, with revenue of $2.804 billion topping the $2.635 billion estimate (+6.4%) while adjusted EPS of $2.62 topped the $1.99 estimate (+31.7%). Revenue rose 14.2% to roughly $2.8 billion (up from $2.455 billion a year ago), alongside gross profit of about $2.1 billion and a gross margin of roughly 73%. Despite the revenue growth, adjusted EPS fell 45.5% year over year to $2.62 (down from $4.81 a year ago). The quarter generated operating cash flow of about $640.8 million. For the next period, consensus calls for EPS of $3.14 on revenue of $2.579 billion.
About Biogen Inc.
Biogen Inc. develops, manufactures, and markets therapies for neurological, neurodegenerative, autoimmune, and blood-related diseases. Listed on NASDAQ as BIIB, the company sits within the healthcare sector as a branded drug maker, and it recorded $9.8 billion in revenue in FY2025.
Today's Snapshot
BIIB ended the day slightly higher at 251.41, while its sector was weaker. At the close, BIIB was within 3.7% of its 52-week high of 261.00. Biogen reported positive two-year results for diranersen, an experimental Alzheimer’s treatment.
Trading Volume
Above 10d avg 999.1K
1.1M
vs S&P 500 Today
Outperforming Market
+0.51%
Updated: November 18, 2026 at 21:20 UTC
BIIB Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$209.54 - $251.15Buy
- RSI (14)56.64Neutral
- Stochastic %K (14, 3, 3)53.73Neutral
- MACD Level (12, 26)4.59Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.